Title	18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Author(s)	Toyonaga, Takuya; Hirata, Kenji; Yamaguchi, Shigeru; Hatanaka, Kanako C.; Yuzawa, Sayaka; Manabe, Osamu; Kobayashi, Kentaro; Watanabe, Shiro; Shiga, Tohru; Terasaka, Shunsuke; Kobayashi, Hiroyuki; Kuge, Yuji; Tamaki, Nagara
Citation	European Journal of Nuclear Medicine and Molecular Imaging, 43(8), 1469-1476 https://doi.org/10.1007/s00259-016-3320-x
Issue Date	2016-07
Doc URL	http://hdl.handle.net/2115/66417
Rights	The final publication is available at link.springer.com
Type	article (author version)
File Information	EurJNuclMedMolImaging43_1469.pdf

[Instructions for use](#)

¹⁸F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumours

T Toyonaga¹, K Hirata¹, S Yamaguchi^{1,2}, KC Hatanaka³, S Yuzawa⁴, O Manabe¹, K Kobayashi¹, S Watanabe¹, T Shiga¹, S Terasaka², H Kobayashi², Y Kuge⁵, N Tamaki¹

¹Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

²Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan

³Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

⁴Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

⁵Department of Molecular Imaging, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Correspondence:

Shigeru Yamaguchi, MD, PhD

Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, Japan 060-8638

Tel: +81-11-706-5987

Fax: +81-11-708-7737

E-mail: yama-shu@med.hokudai.ac.jp

Abstract

Purpose:

Tumour necrosis is one of the indicators of tumour aggressiveness. ^{18}F -fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer to evaluate severe hypoxia in vivo. Because severe hypoxia causes necrosis, we hypothesized that intratumoural necrosis can be detected by FMISO PET in brain tumours regardless of their histopathology. We applied FMISO PET to various types of brain tumours before tumour resection and evaluated the correlation between histopathological necrosis and FMISO uptake.

Methods:

This study included 59 brain tumour patients who underwent FMISO PET/computed tomography before any treatments. According to the pathological diagnosis, the brain tumours were divided into three groups: astrocytomas (group 1), neuroepithelial tumours except for astrocytomas (group 2), and others (group 3). Two experienced neuropathologists evaluated the presence of necrosis in consensus. FMISO uptake in the tumour was evaluated visually and semi-quantitatively using the tumour-to-normal cerebellum ratio (TNR).

Results:

In visual analyses, 26/27 cases in the FMISO-positive group presented with necrosis, whereas 28/32 cases in the FMISO-negative group did not show necrosis. Mean TNRs with and without necrosis were 3.49 ± 0.97 and 1.43 ± 0.42 ($p < 0.00001$) in group 1, 2.91 ± 0.83 and 1.44 ± 0.20 ($p < 0.005$) in group 2, and 2.63 ± 1.16 and 1.35 ± 0.23 ($p < 0.05$) in group 3, respectively. Using a cut-off value of TNR=1.67, which was calculated by normal reference regions of interest, we could predict necrosis with sensitivity, specificity, and accuracy of 96.7%, 93.1%, and 94.9%, respectively.

Conclusions:

FMISO uptake within the lesion indicated the presence of histological micro-necrosis. When we used a TNR of 1.67 as the cut-off value, intratumoural micro-necrosis was sufficiently predictable. Because the presence of necrosis implies a poor prognosis, our results suggest that FMISO PET could provide important information for treatment decisions or surgical strategies of any type of brain tumour.

Key words: necrosis, FMISO PET, hypoxia, brain tumour, biopsy, histology

Introduction

Several subtypes of brain tumour develop intratumoural necrosis, and the presence of necrosis is usually an indicator of malignancy or a prognostic factor [1-4]. Tumour necrosis is well correlated to the mitotic index, increases in cellularity, and a high nucleus to cytoplasm ratio. These findings suggest that necrosis might be correlated to tumour progression and therefore prognosis. Ring-like enhancement of contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) can detect macro-necrosis, but only histopathological examination can detect micro-necrosis. Tumour sampling is no doubt an important method to accurately evaluate tumour characteristics. In contrast, the invasiveness of tumour sampling is a clinical obstacle. Non-invasive prediction of the presence of necrosis would highly affect the treatment strategy.

In this study, we focused on the relationship between hypoxia and necrosis. Hypoxia is well known as a major factor in the induction of necrosis, which can be evaluated using ^{18}F -fluoromisonidazole (FMISO). FMISO is the most widely used positron emission tomography (PET) tracer to visualize severe hypoxia in vivo. It is a derivative of misonidazole (MISO) that is used as a radiosensitizer [5]. Mainly because of cytotoxicity, MISO has not been applied to treatment purposes [6]. Subsequently, FMISO was developed as a hypoxia imaging PET tracer [7, 8]. Several studies have suggested that FMISO accumulation may increase sharply under 10–20 mmHg of partial (p) O_2 [8, 9]. Piert et al. examined 14 pigs to evaluate liver tissue hypoxia induced by segmental arterial hepatic occlusion using dynamic PET scanning. Oxygen distributions were assessed directly by Eppendorf pO_2 measurements. They concluded that the decrease in pO_2 was associated with an increase in the FMISO standardized uptake value (SUV) under pO_2 below 20 mmHg [10, 11]. Bentzen et al. examined mice with mammary carcinoma using FMISO and Eppendorf pO_2 measurement. They reported that FMISO accumulation increased under a median pO_2 of 20 mmHg. In addition, they showed that higher inspired pO_2 reduced FMISO accumulation in the tumour [12].

We previously showed that FMISO accumulation distinguishes glioblastoma (GBM) from other lower-grade gliomas [13]. We hypothesized that FMISO PET could identify intratumoural necrosis not only in gliomas but also any type of brain tumour. To test this hypothesis, we applied FMISO PET to subjects with various types of brain tumours before tumour resection, and evaluated the correlation between histopathological necrosis and FMISO accumulation. We also evaluated the threshold of semi-quantitative values in these subjects, which might predict the presence of necrosis.

Materials and methods

Patients

This study included brain tumour patients who underwent FMISO PET or PET/CT before radiation therapy, chemotherapy, and surgical intervention. Patients who had not undergone tumour resection or biopsy after PET examinations were excluded. Overall, the study population included 59 patients (M:F=33:26, age: 30–85 years). Surgeries were performed at Hokkaido University Hospital or our affiliated hospitals. Detailed surgical procedures are described below. Surgical specimens were collected by the Department of Pathology at Hokkaido University. The study was approved by the Ethics Committee of Hokkaido University Hospital (approval number: 014-0381). Written informed consent was obtained from all patients.

Imaging protocol

All patients underwent MRI and FMISO PET or PET/CT before surgical intervention. MRI sequences included T1-weighted with and without gadolinium enhancement, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) images. The types of MRI scanners depended on the facility.

For FMISO PET, patients were not asked to fast before the study. Static PET scanning was initiated at 4 hours after intravenous injection of 400 MBq FMISO (406.42 ± 35.45 MBq) as recommended previously [14, 15]. PET scanners used in this study were an ECAT HR+ PET scanner (Asahi-Siemens Medical Technologies Ltd., Tokyo, Japan), Biograph 64 PET-CT scanner (Asahi-Siemens Medical Technologies Ltd., Tokyo, Japan), and Gemini TF64 TOF-PET/CT scanner (Hitachi Medical Corporation Ltd, Tokyo, Japan). All scanners were operated in the three-dimensional mode. For the ECAT HR+ scanner, the 10-minute emission acquisition was followed by 3 minute transmission scanning with a $^{68}\text{Ge}/^{68}\text{Ga}$ retractable line source. For Biograph 64 PET/CT and Gemini TF PET/CT scanners, the 10 minute emission acquisition was followed by CT scanning for attenuation correction. Attenuation-corrected radioactivity images were reconstructed using filtered back projection (ECAT and Biograph) or the ordered subset expectation maximization method (Gemini) with a Hann filter of 4 mm full-width at half-maximum.

Visual analysis

Visual assessment of FMISO PET results has been described previously [13]. In this study, two nuclear medicine physicians (radiologist A: Ta.To. and radiologist B: Ke.Ko.) visually interpreted the FMISO PET images. Radiologists A and B have 2 and 6 years experience in PET/CT, respectively. They were blind to the clinical information and MRI results. According to FMISO accumulation, they categorized each image into three categories: *low*, *intermediate*, and *high*. For the final decision, the FMISO-positive group represented images that the two radiologists agreed were *high* FMISO uptake. In contrast, the FMISO-negative group represented images that either radiologist evaluated as *low* or *intermediate* uptake.

Semi-quantitative analysis

The tumour-to-normal cerebellum ratio (TNR) was calculated for semi-quantitative analysis. First, a nuclear medicine physician (Ta.To.) created 15 10-mm-diameter circular regions of interest (ROIs) (five ROIs on each of the axial slices) on both sides of the cerebellar cortex for a total of 30 ROIs per patient. The average values of these regions of the SUV were defined as normal references. The SUV was calculated as $[\text{tissue radioactivity (Bq/ml)}] \times [\text{body weight (g)}] / [\text{injected radioactivity (Bq)}]$. Second, we placed one 30-mm round volume of interest (VOI) containing the voxel of the tumour that showed the highest visual accumulation. The tumour regions were determined with reference to gadolinium-enhanced T1-weighted images. Then, the maximum SUV (SUV_{max}) of the tumour was divided by averaging the cerebellar SUV as the TNR. We adopted the mean + 3SD within cerebellar ROIs as the cut-off value for semi-quantitative analysis to avoid any influence of reconstruction noise, as established for whole-body ^{18}F -fluoro-2-deoxyglucose PET [16].

Surgical procedures

The detailed procedures of PET-guided surgery have been described previously [17]. In brief, all surgeries were

performed using the Neuro-Navigation system (StealthStation[®], Treon[®] or S7[®], Medtronic). Before surgery, FMISO-uptake lesions were superimposed on T1-weighted images with gadolinium enhancement. When the patients underwent biopsy, the biopsy target was set in the FMISO-uptake lesion using the navigation system in cases of an identified FMISO uptake lesion. When the patients underwent maximum tumour resection, FMISO-accumulated areas were contained in the extent of resection as much as possible.

Pathological classification

According to the pathological diagnosis, brain tumours were divided into three groups: astrocytic tumours (group 1), neuroepithelial tumours other than astrocytic tumours (group 2), and other histopathological tumours (group 3). Group 1 included two diffuse astrocytomas (DAs), six anaplastic astrocytomas (AAs), and 17 GBMs. Group 2 included three oligoastrocytomas (OAs), one oligodendroglioma (OL), one central neurocytoma, one anaplastic ependymoma (AE), two anaplastic oligoastrocytomas (AOAs), eight anaplastic oligodendrogliomas (AOs), and five GBMs with an oligodendroglial component (GBMO). Group 3 included six primary central nerve system lymphomas (PCNSLs), two metastatic brain tumours, one craniopharyngioma, one hamartoma, one hemangioblastoma, one atypical meningioma, and one lymphomatoid granulomatosis (LYG) (Table 1).

Assessment of necrosis

Two experienced neuropathologists (Ka.Ha. and Sa.Yu.) assessed each specimen and evaluated the presence of necrosis in consensus. The diagnosis and evaluation were determined by agreement of the two pathologists.

Statistical analysis

All parametric variables are presented as the means $\pm$ SD. The weighted Kappa statistic was employed to evaluate interrater reproducibility of visual analyses. Mean values of the FMISO TNR were compared between groups by the Welch's t-test. Fisher's exact test was employed to examine the relationship between the results of visual analyses and those of histopathological necrosis. The associations between image analysis and histopathological necrosis were examined by receiver operating characteristic (ROC) analysis. The cut-off value was represented within cerebellar ROIs. P-values less than 0.05 were considered statistically significant. R 3.1.2 for Windows and the 'survival' package [18] were used for all statistical analyses.

Results

Histopathological necrosis and diagnosis

Histopathological necroses were observed in 17/17 GBMs (100%), 5/5 GBMOs (100%), 1/8 AOs (12.5%), 1/1 AE (100%), 4/6 PCNSLs (66.6%), and 1/2 metastatic brain tumours (50%), and 1/1 atypical meningioma (100%). Necroses were found in 17/25 cases in group 1, 7/20 cases in group 2, and 6/14 cases in group 3.

Correlation between visual analysis and necrosis

Radiologist A evaluated 27/59 cases (45.8%) as *high* uptake, 5/59 cases (8.5%) as *intermediate* uptake, and 27/59 cases

(45.8%) as *low* uptake. Radiologist B rated 28/59 cases (47.5%) as *high* uptake, 2/59 cases (3.4%) as *intermediate* uptake, and 29/59 cases (49.2%) as *low* uptake (Table 2). The weighted Kappa statistic of interrater reliability for FMISO uptake was very high ($k = 0.92$).

A total of 27/59 images, which were evaluated as *high* FMISO uptake by both radiologists, were categorized as FMISO-positive uptake lesions. A total of 32/59 images, which at least one radiologist evaluated as *intermediate* or *low* FMISO uptake, were categorized as FMISO-negative uptake lesions. The relationship between visual analysis and the presence of necrosis is summarized in Table 3. Fisher's exact test indicated a significant correlation between necrosis and visual assessment in all groups (groups 1, 2, and 3: $p < 0.00001$, $p < 0.001$, and $p < 0.01$, respectively).

The relationship between TNR and visual analysis

The means $\pm$ SD of the TNR for FMISO-positive and -negative uptake lesions were 3.56 ± 0.93 and 1.43 ± 0.24 , respectively. The TNR of the FMISO-positive uptake group was significantly higher than that of the FMISO-negative group ($p < 0.00001$, Welch's t-test). ROC analysis revealed a close correlation between TNR and visual analysis [area under the curve (AUC) = 0.998].

TNR and necrosis

The TNR in group 1 was 3.49 ± 0.97 vs. 1.43 ± 0.42 (with vs. without necrosis), the TNR in group 2 was 2.91 ± 0.83 vs. 1.44 ± 0.20 , and the TNR in group 3 was 2.63 ± 1.16 vs. 1.35 ± 0.23 (Fig. 1). The TNRs of cases with necrosis were significantly higher than those of cases without necrosis in each group (group 1, 2, and 3: $p < 0.00001$, $p < 0.005$, and $p < 0.05$, respectively).

Semi-quantitative analysis

The mean $+ 3SD$ as the cut off value was $TNR = 1.67$. When we divided the patients into two groups with high or low TNRs, the necrosis fraction was 1/28 (3.6%) in the low TNR group and 29/31 (93.5%) in the high TNR group (Fig. 2). The ROC curve towards necrosis and TNR including all cases is shown in Fig. 3. The AUC was 0.990. At the cut-off value ($TNR = 1.67$), the sensitivity, specificity, and accuracy were 96.7%, 93.1%, and 94.9% respectively.

Illustrative case

One illustrative case with multifocal GBM was presented. The patient was an 80-year-old female presenting with motor dominant aphasia. MRI revealed two contrast-enhanced lesions in the left frontal lobe. These lesions showed different uptake patterns of FMISO PET. One lesion showed FMISO-positive uptake, whereas the other showed FMISO-negative uptake (Fig. 4A). Biopsies were performed to target each lesion. A specimen from the FMISO-positive lesion showed clear necrosis, whereas the specimen from the FMISO-negative lesion did not show necrosis (Fig. 4B).

Discussion

In this study, both visual and semi-quantitative analyses indicated a strong correlation between the FMISO uptake status and the presence of necrosis. The correlations were significant not only in astrocytic tumours, but also in various histological types of brain tumour. Our results suggest that FMISO PET can predict pathological necrosis regardless of

the histopathological subtypes.

It is well established that FMISO PET can image regional hypoxia. In addition, the mechanisms of FMISO uptake have been described previously [19]. Once FMISO is delivered to cells, retention of FMISO requires, as the first step, electron release from the electron transport chain into the cytosol where the electrons react with the electron-affinic nitro group. Thus, FMISO does not accumulate in necrotic cells itself but rather in peri-necrotic hypoxic cells. Essentially, as tumour cells proliferate, an insufficient oxygen supply may cause local hypoxia [20]. Even though malignant tumour cells are resistant to such severe circumstances, a fraction of cells would fail to survive and thus undergo necrosis [21]. It appears that both the presence of intratumoural micro-necrosis and FMISO uptake have certain thresholds of pO_2 pressure. Our results of strong agreement between necrosis and FMISO uptake suggest that the thresholds are close to each other.

A major result of this study was that FMISO PET could also visualize histologically detectable intratumoural micro-necrosis in vivo. So far, central necrosis is an important finding in malignant brain tumours, and wide-ranging necrosis can be clearly detected by conventional MRI. However, histological micro-necrosis is also important for the diagnosis of malignant brain tumours, especially GBM, because the presence of micro-necrosis is critical information for GBM diagnosis regardless of imaging central necrosis [2]. In addition, atypical and anaplastic meningiomas frequently have histopathological necrosis, and the patient outcomes of these tumours are usually poorer than those of ordinary meningiomas [1, 22].

In this context, FMISO-positive areas might indicate not only severe hypoxic areas (necrotic areas), but also malignant parts of the tumour. FMISO PET might be able to visualize the tumour malignancy in many types of brain tumours. In fact, there are several lines of evidence showing that FMISO-positive lesions are associated with tumour malignancy. These studies indicated that a large volume of hypoxia in glioma measured by FMISO PET is strongly associated with a poorer prognosis [23-26].

Another application of FMISO PET in clinical practice is providing important information for biopsy. Brain tumours, especially gliomas, have histological heterogeneity. Therefore, FMISO may contribute to determining the biopsy site as well as accurate diagnosis of the histological malignancy of these tumours. In addition, FMISO uptake evaluation is reproducible and simple, thus providing valid information [27]. The visual evaluations of the two radiologists were very well correlated in the current study. In the illustrative case, intratumoural FMISO accumulation was heterogeneous within individual tumours, and the presence of necrosis corresponded with the FMISO uptake (Fig. 4).

FMISO PET can provide prognostic information immediately and non-invasively. Clinical symptoms often progress rapidly in brain tumour patients. In such cases, FMISO PET findings might be able to quickly provide information to evaluate necrosis as well as information for differential diagnosis. Furthermore, some cases would benefit from omission of biopsy based on FMISO PET examination, especially elderly patients or patients with severe complications.

Semi-quantitative analysis may be informative for evaluation of FMISO PET. When cases presented with equivocal FMISO accumulation, the visual evaluations by multiple radiologists did not always correspond. In this study, we defined these cases as FMISO negative. In contrast, semi-quantitative analysis could more definitely evaluate these intermediate FMISO uptakes. $TNR = 1.67$ might be an adequate cut-off value for the prediction of necrosis. Therefore, we should consider the TNR when evaluating FMISO PET, especially in lesions that show equivocal FMISO uptake. In fact, there were four cases of exceptions in visual analysis. Two cases in group 2 and two cases in group 3 with necrosis-positive samples showing FMISO-negative uptake. One of the group 2 cases, which were diagnosed as AO, had a TNR of 2.00,

and AE had a TNR of 1.81. Moreover, the two nuclear medicine physicians both evaluated the same area as *intermediate* or *high*. Therefore, FMISO uptake in this case may be a significant finding. On the other hand, two cases in group 3 diagnosed as PCNSL showed lower TNRs, and visual analysis did not indicate a matched area. We considered that there might be other mechanisms of necrosis induction in PCNSL.

The potential pitfall of the correlation between FMISO and necrosis may be treatment-induced necrotic changes resulting from steroids or other chemotherapeutic drugs administered before tumour sampling. Such changes may also affect pathological evaluation. To avoid this possibility, we excluded patients who underwent any treatments before FMISO PET and tumour sampling.

One of the limitations of this study was the small numbers of patients, especially in group 3. The tolerance to hypoxia might be different among histopathological features. We are also interested in evaluating protein expression, gene mutations, and any other differences between FMISO uptake-positive and -negative lesions. Further studies, especially of non-glioma patient populations, are necessary to verify our results and clarify the molecular fundamentals.

Conclusion

This study demonstrated a strong correlation between the presence of necrosis and FMISO uptake. Regardless of pathological subtypes, FMISO uptake within the lesion indicated the presence of necrosis. Our results suggest that FMISO PET could provide important information for treatment decisions and surgical strategies of any type of brain tumour.

Acknowledgements

The authors thank the staff at the Departments of Nuclear Medicine, Molecular Imaging, Radiology, Neurosurgery, and Cancer Pathology of Hokkaido University Graduate School of Medicine, and Department of Surgical Pathology of Hokkaido University Hospital.

Compliance with Ethical Standards

The authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

References

1. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K et al. Pathodiagnostic parameters for meningioma grading. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2008;15(12):1370-5. doi:10.1016/j.jocn.2007.12.005.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. *Acta neuropathologica*. 2007;114(2):97-109. doi:10.1007/s00401-007-0243-4.
3. Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2006;24(34):5419-26. doi:10.1200/JCO.2006.08.1497.
4. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *Journal of neurosurgery*. 2001;95(2):190-8. doi:10.3171/jns.2001.95.2.0190.
5. Urtasun R, Band P, Chapman JD, Feldstein ML, Mielke B, Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. *The New England journal of medicine*. 1976;294(25):1364-7. doi:10.1056/NEJM197606172942503.
6. Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 1985;3(2):97-115.
7. Van Os-Corby DJ, Koch CJ, Chapman JD. Is misonidazole binding to mouse tissues a measure of cellular pO₂? *Biochemical pharmacology*. 1987;36(20):3487-94.
8. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. *Radiation research*. 1990;122(3):301-8.
9. Kavanagh MC, Sun A, Hu Q, Hill RP. Comparing techniques of measuring tumor hypoxia in different murine tumors: Eppendorf pO₂ Histogram, [³H]misonidazole binding and paired survival assay. *Radiation research*. 1996;145(4):491-500.
10. Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. *European journal of nuclear medicine*. 1999;26(2):95-109.
11. Piert M, Machulla HJ, Becker G, Aldinger P, Winter E, Bares R. Dependency of the [¹⁸F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. *Nuclear medicine and biology*. 2000;27(8):693-700.
12. Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumours by [¹⁸F]fluoromisonidazole PET and pO₂ electrode measurements. Influence of tumour volume and carbogen breathing. *Acta oncologica*. 2002;41(3):304-12.
13. Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H et al. (1)(8)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. *European journal of nuclear medicine and molecular imaging*. 2012;39(5):760-70. doi:10.1007/s00259-011-2037-0.

14. Grunbaum Z, Freau SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 1987;28(1):68-75.
15. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. *Physics in medicine and biology*. 2005;50(10):2209-24. doi:10.1088/0031-9155/50/10/002.
16. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2009;50 Suppl 1:122S-50S. doi:10.2967/jnumed.108.057307.
17. Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H et al. Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. *European journal of nuclear medicine and molecular imaging*. 2015;42(7):1071-80. doi:10.1007/s00259-015-3046-1.
18. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC bioinformatics*. 2011;12:77. doi:10.1186/1471-2105-12-77.
19. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. *Seminars in nuclear medicine*. 2007;37(6):451-61. doi:10.1053/j.semnuclmed.2007.07.001.
20. Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y et al. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. *Seminars in nuclear medicine*. 2015;45(2):136-50. doi:10.1053/j.semnuclmed.2014.10.001.
21. Jenkins WT, Evans SM, Koch CJ. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. *International journal of radiation oncology, biology, physics*. 2000;46(4):1005-17.
22. Yamaguchi S, Terasaka S, Kobayashi H, Asaoka K, Motegi H, Nishihara H et al. Prognostic factors for survival in patients with high-grade meningioma and recurrence-risk stratification for application of radiotherapy. *PloS one*. 2014;9(5):e97108. doi:10.1371/journal.pone.0097108.
23. Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC, Jr. et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. *Cancer research*. 2009;69(10):4502-9. doi:10.1158/0008-5472.CAN-08-3884.
24. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2008;14(9):2623-30. doi:10.1158/1078-0432.CCR-07-4995.
25. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2009;50(1):36-44. doi:10.2967/jnumed.108.055467.
26. Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. *European*

journal of nuclear medicine and molecular imaging. 2014;41(10):1870-8. doi:10.1007/s00259-014-2776-9.

27. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54(2):201-7. doi:10.2967/jnumed.112.109330.

Table 1 Demographics of histopathological diagnosis

	ALL	Group 1	Group 2	Group 3
N	59	25	20	14
Age (range)	30-85	34-85	30-78	32-77
Sex (M:F)	33: 26	8:16	13:7	10:4
Histopathological diagnosis (N)		DA (2) AA (6) GBM (17)	OA (3) OL (1) AE (1) AOA (2) AO (8) GBMO (5) Central neurocytoma (1)	PCNSL (6) LYG (1) Metastatic tumour (2) Craniopharyngioma (1) Hamartoma (1) Hemangioblastoma (1) Atypical meningioma (1)

Numbers in parentheses indicate the number of patients. DA, diffuse astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; OA, oligoastrocytoma; OL, oligodendroglioma; AE, anaplastic ependymoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma; GBMO, GBM with an oligodendroglial component; PCNSL, primary central nervous system lymphoma; LYG, lymphomatoid granulomatosis

Table 2 Interrater correlation for FMISO visual assessment

		Radiologist A		
		<i>high</i>	<i>intermediate</i>	<i>low</i>
Radiologist B	<i>high</i>	27	1	0
	<i>intermediate</i>	0	1	1
	<i>low</i>	0	3	26

Table 3 Existence probability of necrosis by FMISO visual assessment

	Group 1		Group 2		Group 3	
	necrosis +	necrosis -	+	-	+	-
FMISO-positive uptake	17	1	5	0	4	0
FMISO-negative uptake	0	7	2	13	2	8

Figure legends

Fig. 1

Differences and distribution of FMISO TNRs in group 1, 2, 3, and all groups. The mean TNRs of cases with necrosis were 3.49 ± 0.97 in group 1, 2.91 ± 0.83 in group 2, and 2.63 ± 1.16 in group 3, which were significantly higher than those of cases without necrosis in each group (group 1, 2, and 3: * $p < 0.00001$, $^{\dagger}p < 0.005$, and $^{\S}p < 0.05$; Welch's t-test).

Fig. 2

Necrosis fractions in high TNR (≥ 1.67) and low TNR (< 1.67) groups. Grey area represents negative necrosis. Dark grey area indicates positive necrosis. The necrosis fraction was 1/28 (3.6%) in the low TNR group and 29/31 (93.5%) in the high TNR group.

Fig. 3

ROC curve for the presence of necrosis generated from TNRs including all cases. The ROC curve showed a very good correlation between necrosis and TNR (AUC=0.990). At the cut-off value (TNR = 1.67), the sensitivity, specificity, and accuracy were 96.7%, 93.1%, and 94.9%, respectively.

Fig. 4

Illustrative case with multifocal GBM. MRI revealed two contrast-enhanced lesions in the left frontal lobe. The upper lesion showed FMISO-negative uptake and a TNR of 1.62 (a). This specimen did not contain necrosis. The lower lesion showed FMISO-positive uptake and a TNR of 3.54 (b). This specimen had clearly observed necrosis.

A

B